Management ChangeJun 25, 2026, 04:02 PM
Keros Therapeutics Appoints Anne Prener to Board of Directors
AI Summary
Keros Therapeutics, Inc. announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026. The company highlighted Dr. Prener's extensive experience in clinical development and executive leadership, which is expected to be invaluable in advancing Keros' pipeline and corporate strategy. Dr. Prener expressed enthusiasm for joining Keros, citing its differentiated scientific approach and commitment to addressing unmet patient needs.
Key Highlights
- Keros Therapeutics appointed Anne Prener, M.D., Ph.D., to its Board of Directors.
- The appointment is effective July 1, 2026.
- Dr. Prener brings clinical development expertise and executive leadership experience.
- She previously served as CEO of Imbria Pharmaceuticals, Freeline Therapeutics, and Gyroscope Therapeutics.
- Dr. Prener also held roles at Novo Nordisk and Baxalta, and currently serves on the board of XSpray Pharma.
Price Impact
More from KROS